Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.56 |
| ▸ | CES1 | P23141 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8679252 | 0.90 | CES2 (0.50) | CES2CES1HTTDPP4MEN1 | |
| SCHEMBL16122048 | 0.90 | CES2 (0.54) | CES2CES1HTTDPP4SMN1; SMN2 | |
| SCHEMBL10563656 | 0.87 | CES2 (0.46) | CES2CES1HTTDPP4MEN1 | |
| SCHEMBL2916433 | 0.87 | CES2 (0.52) | CES2CES1HTTDPP4MEN1 | |
| SCHEMBL8755031 | 0.87 | CES2 (0.46) | CES2CES1HTTDPP4SMN1; SMN2 | |
| SCHEMBL26364830 | 0.84 | CES2 (0.48) | CES2CES1HTTDPP4MEN1 | |
| SCHEMBL542808 | 0.82 | CES2 (0.46) | CES2CES1HTTDPP4MEN1 | |
| SCHEMBL8726566 | 0.82 | CES2 (0.46) | CES2CES1HTTDPP4MEN1 | |
| SCHEMBL11701918 | 0.82 | CES2 (0.46) | CES2CES1HTTDPP4SMN1; SMN2 | |
| SCHEMBL8727075 | 0.82 | CES2 (0.41) | CES2CES1HTTDPP4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881837-B2 | Generation of s-adenosyl-L-methionine; generate s-adenosyl-l-methionine, methylate, recover s-adenosyl-l-methionine | ORCHID CHEMICALS & PHARMACEUTICALS LTD. (IN) | 2005-04-19 | — | — | US | claimed |
| WO-2003002588-A1 | CHEMICAL SYNTHESIS OF S-ADENOSYL-L-METHIONINE WITH ENRICHMENT OF (S,S)-ISOMER | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-01-09 | — | — | WO | claimed |
| US-20020188116-A1 | Chemical synthesis of S-adenosyl-L-methionine with enrichment of ( S,S)-isomer | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED, INDIA (IN) | 2002-12-12 | — | — | US | claimed |
| US-7667034-B2 | Chemical synthesis of S-adenosyl-L-methionine with enrichment of (S,S)-isomer | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2010-02-23 | — | — | US | disclosed |
| US-20080103303-A1 | Chemical Synthesis Of S-Adenosyl-L-Methionine With Enrichment Of (S,S)-Isomer | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2008-05-01 | — | — | US | disclosed |
| EP-1812454-A2 | CHEMICAL SYNTHESIS OF S-ADENOSYL-L-METHIONINE WITH ENRICHMENT OF (S,S)-ISOMER | Orchid Chemicals and Pharmaceuticals Ltd (IN) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006000883-A2 | CHEMICAL SYNTHESIS OF S-ADENOSYL-L-METHIONINE WITH ENRICHMENT OF (S,S)-ISOMER | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2006-01-05 | — | — | WO | disclosed |
| US-6881837-B2 | Generation of s-adenosyl-L-methionine; generate s-adenosyl-l-methionine, methylate, recover s-adenosyl-l-methionine | ORCHID CHEMICALS & PHARMACEUTICALS LTD. (IN) | 2005-04-19 | — | — | US | disclosed |
| WO-2003002588-A1 | CHEMICAL SYNTHESIS OF S-ADENOSYL-L-METHIONINE WITH ENRICHMENT OF (S,S)-ISOMER | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-01-09 | — | — | WO | disclosed |
| US-20020188116-A1 | Chemical synthesis of S-adenosyl-L-methionine with enrichment of ( S,S)-isomer | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED, INDIA (IN) | 2002-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103303-A1 | Chemical Synthesis Of S-Adenosyl-L-Methionine With Enrichment Of (S,S)-Isomer | BHMT2, BHMT, MAT2A | CES2 1723/4885CES1 625/4885HTT 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.